Petros highlights Trump executive order on Rx-to-OTC reclassification reforms

Petros Pharmaceuticals (PTPI) highlights President Trump’s April 15, 2025 Executive Order, titled, “Lowering Drug Prices By Once Again Putting Americans First”, as a demonstration that the Company’s recent strategic shift is well timed to the current regulatory climate, where Petros believes it has already made significant advancements. Petros’ development of its Big Data and AI-driven software-as-a-Medical Device platform presents an important opportunity for the pharmaceutical industry to contribute to the lowering of drug prices while utilizing an emerging, yet proven, methodology that conforms with FDA guidance to ensure a safe transition from Rx to OTC. Petros CCO Fady Boctor commented, “President Trump’s executive order supports the notion that the under-insured, uninsured, and the American population at large will greatly benefit from expanded access to certain drugs that are currently only available via prescription. Since 2021, Petros has been endeavoring toward the development of its proprietary industry-wide technology-assisted platform that centers around consumer’s preferences, as well as meeting the pharmaceutical manufacturers’ time, cost, and efficiency objectives. We believe that further advancement of this platform could unlock substantial partnership opportunities with pharmaceutical companies seeking to broaden patient access and extend the commercial lifecycle of their products through OTC conversion, and that our work closely supports the intention of the Executive Order, and we anticipate continued progress in development of this service.” The Company is developing this intended licensable platform to provide a variety of services, including patient self-selection tools, electronic health records integration to support appropriate patient use, possible integration with retail pharmacies, and robust cybersecurity and privacy safeguards. The ACNU regulatory framework provides guidelines that are designed to expand access as pharmaceutical companies evaluate various potential switches from prescription to over-the counter availability.